Lorcaserin 10 mg once daily (QD) + Lorcaserin 10 mg twice a day (BID) + Matching Placebo

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Obesity

Conditions

Obesity

Trial Timeline

Dec 1, 2007 → Oct 1, 2010

NCT ID

NCT00603291

About Lorcaserin 10 mg once daily (QD) + Lorcaserin 10 mg twice a day (BID) + Matching Placebo

Lorcaserin 10 mg once daily (QD) + Lorcaserin 10 mg twice a day (BID) + Matching Placebo is a phase 3 stage product being developed by Eisai for Obesity. The current trial status is completed. This product is registered under clinical trial identifier NCT00603291. Target conditions include Obesity.

What happened to similar drugs?

20 of 20 similar drugs in Obesity were approved

Approved (20) Terminated (5) Active (0)

✅exenatide + PlaceboEli LillyApproved

✅TirzepatideEli LillyApproved

✅Micafungin + MicafunginAstellas PharmaApproved

✅MicafunginAstellas PharmaApproved

✅Zonegran + PlaceboEisaiApproved

✅lorcaserin hydrochloride XR + PlaceboEisaiApproved

✅Placebo + TirzepatideEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00603902	Phase 3	Completed	Jan 1, 2008	Aug 1, 2009	Obesity
NCT00603291	Phase 3	Completed	Dec 1, 2007	Oct 1, 2010	Obesity

Competing Products

20 competing products in Obesity

See all competitors

Product	Company	Stage	Hype Score
MK0493	Merck	Phase 2	35
MK0557	Merck	Phase 3	40
AMG 786	Amgen	Phase 1	29
Bimagrumab + Tirzepatide + Bimagrumab Placebo + Tirzepatide Placebo	Eli Lilly	Phase 2	39
Tirzepatide	Eli Lilly	Phase 2	42
exenatide + Placebo	Eli Lilly	Approved	43
Brenipatide	Eli Lilly	Phase 1	36
Orforglipron + Placebo	Eli Lilly	Phase 3	47
TERN-601	Terns Pharmaceuticals	Phase 2	32
MBX 4291 + Placebo	MBX Biosciences	Phase 1	30
PG-102	Rani Therapeutics	Phase 1	26
Orforglipron + Placebo	Eli Lilly	Phase 1	29
Tirzepatide + Placebo	Eli Lilly	Phase 3	40
Eloralintide + Placebo	Eli Lilly	Phase 1	29
Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) + Tirzepatide + Tirzepatide Placebo	Eli Lilly	Phase 2	27
LY3437943 + Midazolam + Warfarin + Caffeine	Eli Lilly	Phase 1	29
Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injection	Skye Bioscience	Phase 2	29
Tirzepatide	Eli Lilly	Approved	50
Adenosine + Regadenoson	Astellas Pharma	Pre-clinical	26
Micafungin + Micafungin	Astellas Pharma	Approved	43